Virologic and immunologic effectiveness at 48 weeks of darunavir–ritonavir-based regimens in treatment-experienced persons living with HIV-1 infection in clinical …
FM Biscione, MR Westin, KM Ribeiro… - Journal of the …, 2014 - journals.sagepub.com
FM Biscione, MR Westin, KM Ribeiro, DL Estevam, SW Cardoso, SB Tenore, LFSP Neto…
Journal of the International Association of Providers of AIDS …, 2014•journals.sagepub.comIntroduction: Published data addressing the effectiveness of darunavir–ritonavir (DRV/r)-
based therapy for multiexperienced patients in developing countries are scarce. This study
evaluated the 48-week virologic and immunologic effectiveness of salvage therapy based
on DRV/r for the treatment of multidrug-experienced HIV-1-infected adults in Brazil. Materials
and Methods: A multicenter retrospective cohort study was carried out with multidrug-
experienced adults who were on a failing antiretroviral therapy and started a DRV/r-based …
based therapy for multiexperienced patients in developing countries are scarce. This study
evaluated the 48-week virologic and immunologic effectiveness of salvage therapy based
on DRV/r for the treatment of multidrug-experienced HIV-1-infected adults in Brazil. Materials
and Methods: A multicenter retrospective cohort study was carried out with multidrug-
experienced adults who were on a failing antiretroviral therapy and started a DRV/r-based …
Introduction
Published data addressing the effectiveness of darunavir–ritonavir (DRV/r)-based therapy for multiexperienced patients in developing countries are scarce. This study evaluated the 48-week virologic and immunologic effectiveness of salvage therapy based on DRV/r for the treatment of multidrug-experienced HIV-1-infected adults in Brazil.
Materials and Methods
A multicenter retrospective cohort study was carried out with multidrug-experienced adults who were on a failing antiretroviral therapy and started a DRV/r-based salvage therapy between 2008 and 2010. The primary effectiveness end point was the proportion of patients with virologic success (plasma HIV-1 RNA <50 copies/mL at week 48).
Results
At 48 weeks, 73% of the patients had HIV-RNA <50 copies/mL and a mean increase of 108 CD4 cells/mm3. Higher baseline viral load, lower baseline CD4 count, younger age, and 3 or more DRV/r-associated resistance mutations were significantly predictive of virologic failure. Concomitant use of raltegravir was strongly associated with virologic success.
Conclusion
The use of DRV/r-based regimens for salvage therapy is an effective strategy in the clinical care setting of a developing country.
Sage Journals以上显示的是最相近的搜索结果。 查看全部搜索结果